Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: A meta-analysis of 47 case-control studies

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Wang, Lin ^a   Wang, Guiying ^a   Lu, Chenqi ^b   Feng, Bo ^a   Kang, Jiuhong ^a  

^a TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN;

ALLELE; ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CAUCASIAN; COLORECTAL CANCER; E CADHERIN GENE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; ETHNIC GROUP; ETHNICITY; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIVER CANCER; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; NASOPHARYNX CANCER; NORTH AMERICAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REGRESSION ANALYSIS; RISK FACTOR; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THYROID CANCER; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER;

ALLELES; CADHERINS; CASE-CONTROL STUDIES; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84863610410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040219     Document Type: Article

References (65)

1. Wong AS, Gumbiner BM, (2003) Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 161: 1191-1203.
2. Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, et al. (2000) A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 60: 873-876.
3. Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW, (2008) The E-cadherin gene polymorphism-160C→A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol 167: 7-14.
4. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
5. Higgins JP, Thompson SG, (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23: 1663-1682.
6. Tobias A, (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8: 15-17.
7. Tobias A, (2000) Update of metainf (abstract). Stata Tech Bull 10: 15.
8. Harbord RM, Egger M, Sterne JA, (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25(20): 3443-3457.
9. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, et al. (2008) Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 37(1): 120-132.
10. Langevin SM, Ioannidis JP, Vineis P, Taioli E, (2010) Genetic Susceptibility to Environmental Carcinogens group (GSEC). Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines. Pharmacogenet Genomics 20(10): 586-597.
11. Fei Y, Hu J, Liu S, Liu X, Wang F, et al. (2010) E-cadherin-160 C/A promoter polymorphism and risk of pancreatic carcinoma in Chinese population. Cancer Genet Cytogenet 197: 25-31.
12. Ben Nasr H, Hamrita B, Batbout M, Gabbouj S, Bouaouina N, et al. (2010) A single nucleotide polymorphism in the E-cadherin gene promoter-160 C/A is associated with risk of nasopharyngeal cancer. Clin Chim Acta 411: 1253-1257.
13. Cattaneo F, Venesio T, Molatore S, Russo A, Fiocca R, et al. (2006) Functional analysis and case-control study of-160C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. Anticancer Res 26: 4627-4632.
14. Li Y, Liang J, Kang S, Dong Z, Wang N, et al. (2008) E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese. Gynecol Oncol 108: 409-414.
15. Chien MH, Chou LS, Chung TT, Lin CH, Chou MY, et al. (2012) Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathologic development of oral cancer. Head Neck. 34: 405-411.
16. Chien MH, Yeh KT, Li YC, Hsieh YH, Lin CH, et al. (2011) Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. J Surg Oncol. 104: 299-304.
17. Wang YX, Zhao L, Wang XY, Liu CM, Yu SG, (2011) Association between E-cadherin (CDH1) polymorphisms and papillary thyroid carcinoma risk in Han Chinese population. Endocrine. 2011 Dec 23. [Epub ahead of print].
18. Jacobs G, Hellmig S, Huse K, Titz A, Rfanke A, et al. (2011) Polymorphisms in the 3'-untranslated region of the CDH1 gene are a risk factor for primary gastric diffuse large B-cell lymphoma. Haematologica. 96: 987-995.
19. Wang GY, Hu XH, Lu CQ, Su CC, Luo SJ, et al. (2008) Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer. Lung Cancer 62: 162-172.
20. Zhang XF, Wang YM, Wang R, Wei LZ, Li Y, et al. (2005) [Correlation of E-cadherin polymorphisms to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. (Article in Chinese). Ai Zheng 24: 513-519.
21. Nakamura A, Shimazaki T, Kaneko K, Shibata M, Matsumura T, et al. (2002) Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res 502: 19-24.
22. Lei H, Sjöberg-Margolin S, Salahshor S, Werelius B, Jandáková E, et al. (2002) CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer 98: 199-204.
23. Yu JC, Hsu HM, Chen ST, Hsu GC, Huang CS, et al. (2006) Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway: a multigenic study on cancer susceptibility. J Biomed Sci 13: 419-432.
24. Grünhage F, Jungck M, Lamberti C, Berg C, Becker U, et al. (2008) Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis 23: 147-154.
25. Tan XL, Nieters A, Kropp S, Hoffmeister M, Brenner H, et al. (2008) The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis. Int J Cancer 122: 2573-2580.
26. Pittman AM, Twiss P, Broderick P, Lubbe S, Chandler I, et al. (2009) The CDH1-160C>A polymorphism is a risk factor for colorectal cancer. Int J Cancer 125: 1622-1625.
27. Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, et al. (2002) Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene 21: 1928-1933.
28. Shin Y, Kim IJ, Kang HC, Park JH, Park HW, et al. (2004) A functional polymorphism (-347 G->GA) in the E-cadherin gene is associated with colorectal cancer. Carcinogenesis 25: 2173-2176.
29. Goto T, Nakano M, Ito S, Ehara H, Yamamoto N, et al. (2007) Significance of an E-cadherin gene promoter polymorphism for risk and disease severity of prostate cancer in a Japanese population. Urology 70: 127-130.
30. Cybulski C, Wokołorczyk D, Jakubowska A, Gliniewicz B, Sikorski A, et al. (2007) DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 79: 44-49.
31. Jonsson BA, Adami HO, Hägglund M, Bergh A, Göransson I, et al. (2004)-160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 109: 348-352.
32. Pookot D, Li LC, Tabatabai ZL, Tanaka Y, Greene KL, et al. (2006) The E-cadherin-160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol 176: 793-796.
33. Bonilla C, Mason T, Long L, Ahaghotu C, Chen W, et al. (2006) E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate 66: 546-556.
34. Kamoto T, Isogawa Y, Shimizu Y, Minamiguchi S, Kinoshita H, et al. (2005) Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population. Jpn J Clin Oncol 35: 158-161.
35. Tsukino H, Kuroda Y, Imai H, Nakao H, Qiu D, et al. (2004) Lack of evidence for the association of E-cadherin gene polymorphism with increased risk or progression of prostate cancer. Urol Int 72: 203-207.
36. Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA, (2002) Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer 100: 683-685.
37. Hajdinjak T, Toplak N, (2004) E-cadherin polymorphism-160C/A and prostate cancer. Int J cancer 109: 401-408.
38. Lindström S, Wiklund F, Jonsson BA, Adami HO, Bälter K, et al. (2005) Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum Genet 118: 339-347.
39. Medina-Franco H, Ramos-De la Medina A, Vizcaino G, Medina-Franco JL, (2007) Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population. Ann Surg Oncol 14: 2246-2249.
40. Yamada H, Shinmura K, Ikeda S, Tao H, Otani T, et al. (2007) Association between CDH1 haplotypes and gastric cancer risk in a Japanese population. Scand J Gastroenterol 42: 1479-1485.
41. Zhang B, Pan K, Liu Z, Zhou J, Gu L, et al. (2008) Genetic polymorphisms of the E-cadherin promoter and risk of sporadic gastric carcinoma in Chinese populations. Cancer Epidemiol Biomarkers Prev 17: 2402-2408.
42. Jenab M, McKay JD, Ferrari P, Biessy C, Laing S, et al. (2008) CDH1 gene polymorphisms, smoking, Helicobacter pylori infection and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Eur J Cancer 44: 774-780.
43. Corso G, Berardi A, Marrelli D, Pedrazzani C, Garosi L, et al. (2009) CDH1 C-160A promoter polymorphism and gastric cancer risk. Eur J Cancer Prev 18: 46-49.
44. Al-Moundhri MS, Al-Khanbashi M, Al-Kindi M, Al-Nabhani M, Burney IA, et al. (2010) Association of E-cadherin (CDH1) gene polymorphisms and gastric cancer risk. World J Gastroenterol 16: 3432-3436.
45. Kuraoka K, Oue N, Yokozaki H, Kitadai Y, Ito R, et al. (2003) Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. Int J Oncol 23: 421-427.
46. Song CG, Huang CM, Liu X, Lu HS, Zhang XF, et al. (2005) [Association of-160(C→A) polymorphism in CDH1 gene with gastric cancer risk in Fujian Chinese population]. (Article in Chinese). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22: 557-559.
47. Lu Y, Xu YC, Shen J, Yu RB, Niu JY, et al. (2005) E-cadherin gene C-160A promoter polymorphism and risk of non-cardia gastric cancer in a Chinese population. World J Gastroenterol 11: 56-60.
48. Park WS, Cho YG, Park JY, Kim CJ, Lee JH, et al. (2003) A single nucleotide polymorphism in the E-cadherin gene promoter-160 is not associated with risk of Korean gastric cancer. J Korean Med Sc 18: 501-504.
49. Wu MS, Huang SP, Chang YT, Lin MT, Shun CT, et al. (2002) Association of the-160 C→A promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 94: 1443-1448.
50. Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo AM, et al. (2002) Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 21: 8192-8195.
51. Pharoah PD, Oliveira C, Machado JC, Keller G, Vogelsang H, et al. (2002) CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer 101: 196-197.
52. Shin Y, Kim IJ, Kang HC, Park JH, Park HR, et al. (2004) The E-cadherin-347G/GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis 25: 895-899.
53. Zhang X, Ma X, Zhu QG, Li LC, Chen Z, et al. (2003) Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol 170: 1379-1382.
54. Ma X, Xu H, Zheng T, Li HZ, Shi TP, et al. (2008) DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder. BJU Int 102: 633-636.
55. Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, et al. (2003) E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett 195: 53-58.
56. Kiemeney LA, van Houwelingen KP, Bogaerts M, Witjes JA, Swinkels DW, et al. (2006) Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. Eur J Cancer 42: 3219-3227.
57. Ricketts C, Zeegers MP, Lubinski J, Maher ER, (2009) Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One 4: e6037.
58. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
59. Wang JH, eds. (2007) Beijing: People's Health Publishing House. ed. (Epidemiology (in Chinese), 6th ed.
60. Akakura S, Huang C, Nelson PJ, Foster B, Gelman IH, (2008) Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res 68: 5096-5103.
61. Alonso-Magdalena P, Brössner C, Reiner A, Cheng G, Sugiyama N, et al. (2009) A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci U S A 106: 2859-2863.
62. Koksal IT, Ishak Y, Usta M, Danisman A, Guntekin E, et al. (2007) Varicocele-induced testicular dysfunction may be associated with disruption of blood-testis barrier. Arch Androl 53: 43-48.
63. Shie JH, Kuo HC, (2011) Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 108: E136-E141.
64. Balding DJ, (2006) A tutorial on statistical methods for population association studies. Nat Rev Genet 7: 781-791.
65. Wittke-Thompson JK, Pluzhnikov A, Cox NJ, (2002) Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 76: 967-986.